You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on Human Metabolome Database.
Record Information
StatusDetected and Quantified
Creation Date2009-07-25 00:12:44 UTC
Update Date2019-01-11 19:32:05 UTC
Secondary Accession Numbers
  • HMDB13072
Metabolite Identification
Common NameSomatostatin
DescriptionSomatostatin is a peptide hormone that regulates the endocrine system and affects neurotransmission and cell proliferation via interaction with G protein-coupled somatostatin receptors and inhibition of the release of numerous secondary hormones. Somatostatin has two active forms produced by alternative cleavage of a single preproprotein: one of 14 amino acids, the other of 28 amino acids
Growth hormone-inhibiting hormone (ghih)HMDB
Somatotropin release-inhibiting factor (srif)HMDB
Somatotropin release-inhibiting hormoneHMDB
Chemical FormulaC77H106N18O19S2
Average Molecular Weight1651.905
Monoisotopic Molecular Weight1650.73230468
IUPAC Name(5S,8R,14R,17R,20R,23R,26R,29R,32R,35R)-20,35-bis(4-aminobutyl)-38-{2-[(2R)-2-aminopropanamido]acetamido}-14,26,29-tribenzyl-32-(carbamoylmethyl)-11-(1-hydroxyethyl)-17-[(1S)-1-hydroxyethyl]-8-(hydroxymethyl)-23-(1H-indol-3-ylmethyl)-7,10,13,16,19,22,25,28,31,34,37-undecaoxo-1,2-dithia-6,9,12,15,18,21,24,27,30,33,36-undecaazacyclononatriacontane-5-carboxylic acid
Traditional Name(5S,8R,14R,17R,20R,23R,26R,29R,32R,35R)-20,35-bis(4-aminobutyl)-38-{2-[(2R)-2-aminopropanamido]acetamido}-14,26,29-tribenzyl-32-(carbamoylmethyl)-11-(1-hydroxyethyl)-17-[(1S)-1-hydroxyethyl]-8-(hydroxymethyl)-23-(1H-indol-3-ylmethyl)-7,10,13,16,19,22,25,28,31,34,37-undecaoxo-1,2-dithia-6,9,12,15,18,21,24,27,30,33,36-undecaazacyclononatriacontane-5-carboxylic acid
CAS Registry NumberNot Available
InChI Identifier
Chemical Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as polypeptides. These are peptides containing ten or more amino acid residues.
KingdomOrganic compounds
Super ClassOrganic Polymers
Sub ClassNot Available
Direct ParentPolypeptides
Alternative Parents
  • Polypeptide
  • Cyclic alpha peptide
  • N-acyl-alpha amino acid or derivatives
  • Macrolactam
  • Alpha-amino acid amide
  • Alanine or derivatives
  • N-substituted-alpha-amino acid
  • Alpha-amino acid or derivatives
  • 3-alkylindole
  • Indole or derivatives
  • Indole
  • Monocyclic benzene moiety
  • Benzenoid
  • Substituted pyrrole
  • Heteroaromatic compound
  • Pyrrole
  • Secondary alcohol
  • Primary carboxylic acid amide
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Lactam
  • Amino acid
  • Organic disulfide
  • Amino acid or derivatives
  • Azacycle
  • Carboxylic acid derivative
  • Carboxylic acid
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Primary amine
  • Organopnictogen compound
  • Organic oxygen compound
  • Organic nitrogen compound
  • Alcohol
  • Carbonyl group
  • Hydrocarbon derivative
  • Organic oxide
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Primary aliphatic amine
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Biological location:


Physical Properties
Experimental Properties
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water SolubilityNot AvailableNot Available
LogPNot AvailableNot Available
Predicted Properties
Water Solubility0.02 g/LALOGPS
pKa (Strongest Acidic)3.01ChemAxon
pKa (Strongest Basic)10.47ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count22ChemAxon
Hydrogen Donor Count22ChemAxon
Polar Surface Area613.23 ŲChemAxon
Rotatable Bond Count26ChemAxon
Refractivity425.02 m³·mol⁻¹ChemAxon
Polarizability170.09 ųChemAxon
Number of Rings6ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectrum TypeDescriptionSplash KeyView
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Positivesplash10-0gc0-1200009000-5e61b49bf8dbb073ed22JSpectraViewer | MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Positivesplash10-0i03-7400089000-034b3963ecb5e88e678bJSpectraViewer | MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Positivesplash10-0fl3-9200031000-a094c26c61bef013c6d6JSpectraViewer | MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Negativesplash10-100s-0000059000-740a0b2a5dcaad57028fJSpectraViewer | MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Negativesplash10-0f83-2000094000-f8adda386e088595a1e4JSpectraViewer | MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Negativesplash10-0006-9200131000-cb8a3b6228933c11504aJSpectraViewer | MoNA
Biological Properties
Cellular LocationsNot Available
Biospecimen Locations
  • Cerebrospinal Fluid (CSF)
Tissue LocationsNot Available
Normal Concentrations
Cerebrospinal Fluid (CSF)Detected and Quantified0.000008289 +/- 0.000004840 uMAdult (>18 years old)Not SpecifiedNormal details
Cerebrospinal Fluid (CSF)Detected and Quantified0.00004447 +/- 0.0000050000 uMAdult (>18 years old)Not SpecifiedNormal details
Cerebrospinal Fluid (CSF)Detected and Quantified0.0000525 +/- 0.0000099 uMAdult (>18 years old)Not SpecifiedNormal details
Cerebrospinal Fluid (CSF)Detected and Quantified0.0000228 +/- 0.0000054 uMNot SpecifiedNot SpecifiedNormal details
Abnormal Concentrations
Cerebrospinal Fluid (CSF)Detected and Quantified0.000050000 +/- 0.000006777 uMChildren (1-13 years old)Not SpecifiedFebrile seizure details
Cerebrospinal Fluid (CSF)Detected and Quantified0.00002136 +/- 0.000002602 uMChildren (1-13 years old)Not Specifiedepilepsy details
Cerebrospinal Fluid (CSF)Detected and Quantified0.00001204 +/- 0.000003267 uMAdult (>18 years old)Not Specifiedpost-traumatic stress disorder  details
Cerebrospinal Fluid (CSF)Detected and Quantified0.00006529 +/- 0.000005869 uMAdult (>18 years old)Not SpecifiedParkinsonian syndrome details
Cerebrospinal Fluid (CSF)Detected and Quantified0.0000204 +/- 0.0000081 uMAdult (>18 years old)Not SpecifiedParkinson's Disease details
Associated Disorders and Diseases
Disease References
Parkinson's disease
  1. Dizdar N, Kagedal B, Lindvall B: Treatment of Parkinson's disease with NADH. Acta Neurol Scand. 1994 Nov;90(5):345-7. [PubMed:7887134 ]
Febrile seizures
  1. Hirai K, Seki T: Cerebrospinal fluid somatostatin levels in febrile seizures and epilepsy in children. Neuropeptides. 2000 Feb;34(1):18-24. [PubMed:10688964 ]
  1. Hirai K, Seki T: Cerebrospinal fluid somatostatin levels in febrile seizures and epilepsy in children. Neuropeptides. 2000 Feb;34(1):18-24. [PubMed:10688964 ]
Parkinsonian syndrome
  1. Espino A, Calopa M, Ambrosio S, Ortola J, Peres J, Navarro MA: CSF somatostatin increase in patients with early parkinsonian syndrome. J Neural Transm Park Dis Dement Sect. 1995;9(2-3):189-96. [PubMed:8527003 ]
Associated OMIM IDs
DrugBank IDNot Available
Phenol Explorer Compound IDNot Available
FoodDB IDFDB029283
KNApSAcK IDNot Available
Chemspider IDNot Available
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkSomatostatin
METLIN IDNot Available
PubChem Compound53481605
PDB IDNot Available
ChEBI IDNot Available
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General References
  1. Shen LP, Pictet RL, Rutter WJ: Human somatostatin I: sequence of the cDNA. Proc Natl Acad Sci U S A. 1982 Aug;79(15):4575-9. [PubMed:6126875 ]
  2. Shen LP, Rutter WJ: Sequence of the human somatostatin I gene. Science. 1984 Apr 13;224(4645):168-71. [PubMed:6142531 ]
  3. Liu Y, Lu D, Zhang Y, Li S, Liu X, Lin H: The evolution of somatostatin in vertebrates. Gene. 2010 Sep 1;463(1-2):21-8. doi: 10.1016/j.gene.2010.04.016. Epub 2010 May 21. [PubMed:20472043 ]